RESUMO
Bisphenol AF (BPAF) is now recognized as one of the replacements for bisphenol A (BPA). Although considerable experimental evidence suggests that BPA is an endocrine-disrupting chemical, the toxicological profile of BPAF has been investigated in less detail than that of BPA, even at the in vitro level. BPAF has been established as an activator of estrogen receptor α (ERα) in many cell lines; however, controversy surrounds its effects on the other isoform, ERß (i.e., whether it functions as a stimulator). Five human ERß isoforms have been cloned and characterized. Of these, we focused on the interactions between BPAF and the two isoforms, ERß1 and ERß2. We demonstrated that i) BPAF functioned as a stimulator of ERß1 (and ERα), which is transiently expressed in the two types of human breast cancer cells (MDA-MB-231 and SK-BR-3 cells) (EC50 values for ERß: 6.87 nM and 2.58 nM, respectively, and EC50 values for ERα: 24.7 nM and 181 nM, respectively), ii) the stimulation of ERß1 by BPAF (1-25 nM) was abrogated by PHTPP (an ERß selective antagonist), and iii) the expression of ERß1 and ERß2 was not modulated by BPAF at nanomolar concentrations up to 25 nM. These results indicate that BPAF activates not only human ERα, but also the ERß1 isoform in breast cancer cells, and exhibits higher activation potency for ERß1.
